Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

21. Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents

Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents 27747804 2018 11 13 2199-1154 3 1 2016 Mar Drugs - real world outcomes Drugs Real World Outcomes Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents. 53-60 Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid (...) -related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with other intranasal steroids (INS). After a feasibility study using an electronic medical record database in the UK (1990-2002), a retrospective cohort study was conducted using a large administrative claims database in the USA from 1994 to 2002 comparing the incidence and rate ratios of steroid-related events among intermittent, sub-chronic, and chronic FPNS use and other INS use episodes. Most patients

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

22. Fluticasone Furoate and Vilanterol (as trifenatate) (Breo Ellipta)

Fluticasone Furoate and Vilanterol (as trifenatate) (Breo Ellipta) Fluticasone Furoate and Vilanterol (as trifenatate) | CADTH.ca Find the information you need Fluticasone Furoate and Vilanterol (as trifenatate) Fluticasone Furoate and Vilanterol (as trifenatate) Last Updated: June 30, 2015 Result type: Reports Project Number: SR0442-000 Product Line: Generic Name: Fluticasone Furoate and Vilanterol (as trifenatate) Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Asthma

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

23. Fluticasone Furoate and Vilanterol (as trifenatate) (Breo Ellipta)

Fluticasone Furoate and Vilanterol (as trifenatate) (Breo Ellipta) Fluticasone Furoate and Vilanterol (as trifenatate) | CADTH.ca Find the information you need Fluticasone Furoate and Vilanterol (as trifenatate) Fluticasone Furoate and Vilanterol (as trifenatate) Last Updated: June 30, 2015 Result type: Reports Project Number: SR0442-000 Product Line: Generic Name: Fluticasone Furoate and Vilanterol (as trifenatate) Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Asthma

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

24. Fluticasone furoate (TBC)

Fluticasone furoate (TBC) Fluticasone furoate | CADTH.ca Find the information you need Fluticasone furoate Fluticasone furoate Last Updated: May 4, 2015 Result type: Reports Project Number: SR0439-000 Product Line: Generic Name: Fluticasone furoate Brand Name: Arnuity Ellipta Manufacturer: GlaxoSmithKline Inc. Indications: Asthma Submission Type: New Project Status: Active Date Recommendation Issued: December 17, 2015 Recommendation Type: List with criteria/condition Tags asthma Files Follow us

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

25. Effect of fluticasone propionate on virus-induced airways inflammation and anti-viral immune responses in mice.

Effect of fluticasone propionate on virus-induced airways inflammation and anti-viral immune responses in mice. BACKGROUND: Inhaled corticosteroids are commonly used in the treatment of asthma and chronic obstructive pulmonary disease, but their effects on viral loads and anti-viral responses are poorly characterised. The aim of this study was to assess effects of inhaled fluticasone propionate on rhinovirus infection in vivo, in a mouse model. We tested the hypothesis that this treatment would (...) reduce virus-induced airways inflammation but that the effect would be confounded by interference with anti-viral immune responses, leading to delayed viral clearance. METHODS: C57BL/6 mice were intranasally dosed with fluticasone propionate (1 mg/kg) or vehicle (dimethyl sulfoxide, control), 1 h before infection with rhinovirus 1B. We assessed bronchoalveolar lavage (BAL) inflammatory cell numbers, and measured gene expression, protein production of innate mediators, or both by quantitative RT-PCR

Lancet2015

26. Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)

Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Fluticasone furoate (...) /vilanterol (as trifenatate) (Relvar® Ellipta®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2014. 2014 Authors' conclusions Fluticasone furoate/vilanterol (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2

Health Technology Assessment (HTA) Database.2015

27. Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)

Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Fluticasone furoate (...) /vilanterol (as trifenatate) (Relvar® Ellipta®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1014. 2014 Authors' conclusions Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV1< 70% predicted normal (post-bronchodilator

Health Technology Assessment (HTA) Database.2015

28. Azelastine hydrochloride + fluticasone propionate (Dymista) - seasonal and perennial allergic rhinitis

Azelastine hydrochloride + fluticasone propionate (Dymista) - seasonal and perennial allergic rhinitis

Scottish Medicines Consortium2014

29. Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis

Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis HAS - Medical, Economic and Public Health Assessment Division 1/17 Opinion 2 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 DYMISTA 137 µg/50 µg, nasal spray suspension Bottle with 23 g suspension of 25 ml or around 120 doses (CIP: 34009 275 631 1 9 (...) ) Applicant: MEDA PHARMA INN Azelastine hydrochloride, fluticasone propionate. ATC Code (2013): R01AD58 (nasal corticosteroid, combinations) Reason for the request Inclusion Lists concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indications concerned "Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient

Haute Autorite de sante2014

30. Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) - for the regular treatment of asthma

Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) - for the regular treatment of asthma Final Appraisal Recommendation Advice No: 2014 – July 2014 Fluticasone furoate/vilanterol (as trifenatate) (Relvar ® Ellipta ® ? ) 92/22 micrograms and 184/22 micrograms inhalation powder Submission by GlaxoSmithKline In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1216), which includes the AWMSG (...) of AWMSG Fluticasone furoate/vilanterol (Relvar ® Ellipta ® ? ) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: ? patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists. Statement of use: No part of this recommendation may be reproduced

All Wales Medicines Strategy Group2014

31. Fluticasone furoate / vilanterol (Relvar Ellipta) - treatment of asthma in adults and adolescents aged 12 years and older

Fluticasone furoate / vilanterol (Relvar Ellipta) - treatment of asthma in adults and adolescents aged 12 years and older

Scottish Medicines Consortium2014

32. Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) for chronic obstructive pulmonary disease

Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta) for chronic obstructive pulmonary disease Final Appraisal Recommendation Advice No: 1014 – May 2014 Fluticasone furoate/vilanterol (as trifenatate) (Relvar ® Ellipta ® ? ) 92 micrograms/22 micrograms inhalation powder Submission by GlaxoSmithKline Additional note: ? Fluticasone furoate/vilanterol (as trifenatate) (Relvar ® Ellipta ® ? ) should be used in line with NICE Clinical Guideline on chronic obstructive pulmonary disease (...) by Welsh Government and will be considered for review every three years. Marketing authorisation holder on first issue: GlaxoSmithKline Date of first issue May 2014 Last reviewed May 2017 Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1534: fluticasone furoate/vilanterol (as trifenatate) 92 micrograms/22 micrograms inhalation powder May 2014

All Wales Medicines Strategy Group2014

33. Fluticasone furoate/vilanterol (Relvar Ellipta) - symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD)

Fluticasone furoate/vilanterol (Relvar Ellipta) - symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD)

Scottish Medicines Consortium2014

34. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol (...) and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of switching typical asthma patients to extra-fine particle beclometasone-formoterol (efBDP-FOR) treatment. The authors concluded that switching asthma patients from fluticasone propionate and salmeterol (FP-SAL) to efBDP-FOR at an equivalent or lower dose was both less costly and more effective. The analysis and results appear to support the authors' conclusions but some uncertainty remains due to the study design and cost

NHS Economic Evaluation Database.2014

35. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone 24253831 2014 03 10 2014 04 29 2017 02 20 1468-3296 69 4 2014 Apr Thorax Thorax Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. 312-9 10.1136/thoraxjnl-2013-203600 Combination therapy with an inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone (...) . However, there is ongoing debate regarding the risk-benefit ratio of using LABA in asthma. To evaluate the effect of the addition of a novel LABA, vilanterol (VI), to a once-daily ICS, fluticasone furoate (FF), on the risk of severe asthma exacerbations in patients with uncontrolled asthma. This randomised double-blind comparative study of variable duration (≥ 24-78 weeks) was designed to finish after 330 events (each patient's first on-treatment severe asthma exacerbation). 2019 patients with asthma

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

36. Revinty Ellipta - fluticasone furoate / vilanterol

Revinty Ellipta - fluticasone furoate / vilanterol 20 March 2014 EMA/CHMP/175905/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Revinty Ellipta International non-proprietary name: fluticasone furoate / vilanterol Procedure No. EMEA/H/C/002745/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union (...) Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Product information Name of the medicinal product: Revinty Ellipta Applicant: Glaxo Group Ltd Glaxo Group Ltd 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom Active substance: Fluticasone furoate / vilanterol trifenatate International Nonproprietary Name Fluticasone furoate

European Medicines Agency - EPARs2014

37. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler Asthma: fluticasone furoate/vilanterol (Relvar Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler Ellipta) combination inhaler Evidence summary Published: 3 March 2014 nice.org.uk/guidance/esnm34 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national (...) formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Relvar Ellipta is a combination inhaler containing 2 active ingredients not previously available for the treatment of asthma: fluticasone furoate (an inhaled corticosteroid [ICS]) and vilanterol (a long- acting beta-2 agonist [LABA]). There are no published studies that compare fluticasone furoate/ vilanterol with a currently available ICS/LABA combination inhaler or currently available ICS

National Institute for Health and Clinical Excellence - Advice2014

38. Azelastine - HCl and fluticasone propionate

Azelastine - HCl and fluticasone propionate Azelastine - HCl and fluticasone propionate Azelastine - HCl and fluticasone propionate CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Azelastine - HCl and fluticasone propionate. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review. 2014 Authors (...) ' conclusions The Canadian Drug Expert Committee (CDEC) recommends that azelastine hydrochloride/ fluticasone propionate (AZE/FP) not be listed for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults and adolescents aged 12 years and older for whom monotherapy with either antihistamines or intranasal corticosteroids is not considered sufficient. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Rhinitis

Health Technology Assessment (HTA) Database.2014

39. Cohort study: Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD

Cohort study: Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Article Text Harm Cohort study Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD Patrick White Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Suissa S , Patenaude V

Evidence-Based Medicine (Requires free registration)2014

40. Fluticasone furoate vilanterol (Breo Ellipta ? GlaxoSmithKline) indication: chronic obstructive pulmonary disease

Fluticasone furoate vilanterol (Breo Ellipta ? GlaxoSmithKline) indication: chronic obstructive pulmonary disease Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0358. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that fluticasone furoate/vilanterol (FF/V) be listed for the long-term, once-daily maintenance treatment of airflow obstruction in patients

Health Technology Assessment (HTA) Database.2014